Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLoans and Notes ReceivablesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Gyre Therapeutics (GYRE) Other Gross PP&E Adjustments (2016 - 2026)

Gyre Therapeutics has reported Other Gross PP&E Adjustments over the past 16 years, most recently at $29.7 million for Q4 2025.

  • Quarterly Other Gross PP&E Adjustments rose 9.99% to $29.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $29.7 million through Dec 2025, up 9.99% year-over-year, with the annual reading at $29.7 million for FY2025, 9.99% up from the prior year.
  • Other Gross PP&E Adjustments was $29.7 million for Q4 2025 at Gyre Therapeutics, down from $30.0 million in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at $30.0 million in Q3 2025 and troughed at -$3.3 million in Q4 2021.
  • The 5-year median for Other Gross PP&E Adjustments is $19.6 million (2022), against an average of $13.5 million.
  • Year-over-year, Other Gross PP&E Adjustments plummeted 87.17% in 2021 and then soared 162364.71% in 2024.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at -$3.3 million in 2021, then soared by 703.26% to $19.6 million in 2022, then soared by 33.65% to $26.2 million in 2023, then grew by 2.92% to $27.0 million in 2024, then grew by 9.99% to $29.7 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Other Gross PP&E Adjustments are $29.7 million (Q4 2025), $30.0 million (Q3 2025), and $29.0 million (Q2 2025).